BeyondSpring Inc.: directors' dealings · United States · SEC (Form 4)

About BeyondSpring Inc.

BeyondSpring Inc. is a U.S.-listed biopharmaceutical company traded on the NASDAQ in the United States, focused on innovative oncology therapies and, more broadly, treatments for cancer and select other diseases. The company is best known for plinabulin, its lead clinical-stage asset, which has been developed for high-unmet-need oncology settings, including non-small cell lung cancer. BeyondSpring is still a clinical-stage company, so its investment case is driven primarily by clinical progress, regulatory milestones, and capital allocation rather than by large-scale commercial revenues. The company was built around a research platform centered on immuno-oncology and has organized its pipeline and strategy around a narrow set of priorities: advancing plinabulin across oncology indications, generating late-stage confirmatory data, and selectively managing complementary assets. A notable strategic element has been BeyondSpring’s equity interest in SEED Therapeutics, which the company has partially monetized to help fund late-stage development of plinabulin. For investors, this creates a classic biotech profile: concentrated pipeline exposure, high binary risk, and meaningful upside if pivotal studies and regulatory discussions progress favorably. From a competitive standpoint, BeyondSpring operates in one of the most crowded areas of healthcare, competing against large pharmaceutical companies, oncology-focused biotech peers, and established treatment options. Its differentiation lies in the novelty of its lead asset, its focus on patient populations with significant unmet need, and the potential to convert clinical data into regulatory value through carefully sequenced development programs. It is not a broad commercial platform company; rather, it is a specialized biotechnology name where scientific execution matters more than scale. The company is headquartered in Florham Park, New Jersey, United States. Recent company communications indicate a continued emphasis on late-stage study execution, including plans for a confirmatory global phase 3 program, along with tighter financial discipline. 2025 updates also highlighted clinical progress for Plinabulin and strategic developments related to the company’s stake in SEED Therapeutics. BeyondSpring also remains visible through regular SEC filings, including Form 4 insider transaction reports, which underscores the market’s focus on ownership changes and capital structure. For French- and European-based investors, BeyondSpring is best viewed as a U.S. NASDAQ-listed small-cap biotech with a focused oncology pipeline and significant catalyst-driven volatility.